NASDAQ:EGRX - Eagle Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$65.36 -3.23 (-4.71 %)
(As of 05/20/2018 04:00 PM ET)
Previous Close$65.36
Today's Range$65.18 - $69.1750
52-Week Range$45.05 - $84.20
Volume282,420 shs
Average Volume248,082 shs
Market Capitalization$969.62 million
P/E Ratio19.39
Dividend YieldN/A
Beta1.39

About Eagle Pharmaceuticals (NASDAQ:EGRX)

Eagle Pharmaceuticals logoEagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL). Its product candidates includes include EP-3101, (bendamustine ready-to-dilute) for CLL and indolent B-cell NHL; EP-4104, a dantrolene sodium for exertional heat stroke; EGL-4104-C-1702, dantrolene sodium for drug induced hyperthermia; EP-5101 (pemetrexed) for lung cancer and mesothelioma; and EGL-5385-C-1701 (fulvestrant) for breast cancer. Eagle Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Receive EGRX News and Ratings via Email

Sign-up to receive the latest news and ratings for EGRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EGRX
CUSIPN/A
Phone201-326-5300

Debt

Debt-to-Equity Ratio0.23
Current Ratio5.87
Quick Ratio5.66

Price-To-Earnings

Trailing P/E Ratio19.39
Forward P/E Ratio34.04
P/E GrowthN/A

Sales & Book Value

Annual Sales$236.71 million
Price / Sales4.10
Cash Flow$3.8583 per share
Price / Cash16.94
Book Value$12.01 per share
Price / Book5.44

Profitability

EPS (Most Recent Fiscal Year)$3.37
Net Income$51.94 million
Net Margins15.32%
Return on Equity21.89%
Return on Assets15.09%

Miscellaneous

Employees108
Outstanding Shares14,840,000

Eagle Pharmaceuticals (NASDAQ:EGRX) Frequently Asked Questions

What is Eagle Pharmaceuticals' stock symbol?

Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."

How will Eagle Pharmaceuticals' stock buyback program work?

Eagle Pharmaceuticals announced that its board has authorized a stock repurchase program on Thursday, August 10th 2017, which authorizes the company to repurchase $100,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to reacquire up to 13.3% of its stock through open market purchases. Stock repurchase programs are often a sign that the company's leadership believes its stock is undervalued.

How were Eagle Pharmaceuticals' earnings last quarter?

Eagle Pharmaceuticals (NASDAQ:EGRX) announced its earnings results on Thursday, May, 10th. The specialty pharmaceutical company reported $0.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.68 by $0.15. The specialty pharmaceutical company had revenue of $46.60 million for the quarter, compared to the consensus estimate of $48.88 million. Eagle Pharmaceuticals had a return on equity of 21.89% and a net margin of 15.32%. The company's revenue for the quarter was down 39.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.42 earnings per share. View Eagle Pharmaceuticals' Earnings History.

What price target have analysts set for EGRX?

3 analysts have issued twelve-month price targets for Eagle Pharmaceuticals' shares. Their forecasts range from $54.00 to $79.00. On average, they anticipate Eagle Pharmaceuticals' share price to reach $68.00 in the next twelve months. View Analyst Ratings for Eagle Pharmaceuticals.

What are Wall Street analysts saying about Eagle Pharmaceuticals stock?

Here are some recent quotes from research analysts about Eagle Pharmaceuticals stock:
  • 1. Mizuho analysts commented, "We don’t yet have this product in our model, and don’t expect it to be a meaningful revenue generator because Treanda powder currently has minimal market share. Big bag" may provide insurance if Eagle fails to bar Treanda generics from the market via its Orphan Drug litigation, in our view. The Fulvestrant clinical trial is fully enrolled, and data are expected in the fall. Additionally, the FDA accepted Eagle’s Vasostrict ANDA, which Endo indicated would be subject to the full litigation pathway. We have no estimates for the Ryanodex program for nerve agent exposure and note that Eagle did not provide an update on its drug- induced hyperthermia program, which we believe could get dropped. We summarize 1Q:18 performance below and reiterate our Underperform rating." (5/10/2018)
  • 2. According to Zacks Investment Research, "Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey. " (3/1/2018)

Who are some of Eagle Pharmaceuticals' key competitors?

Who are Eagle Pharmaceuticals' key executives?

Eagle Pharmaceuticals' management team includes the folowing people:
  • Mr. Scott L. Tarriff, Chief Exec. Officer and Director (Age 58)
  • Mr. David M. Pernock, Pres and Chief Commercial Officer (Age 65)
  • Dr. Adrian Hepner M.D., Ph.D., Chief Medical Officer and Exec. VP (Age 57)
  • Mr. Pete A. Meyers, Chief Financial Officer and Principal Accounting Officer (Age 48)
  • Mr. Daniel O'Connor, Exec. VP of Biologics and Corp. Devel. (Age 38)

Has Eagle Pharmaceuticals been receiving favorable news coverage?

Media headlines about EGRX stock have trended somewhat negative on Sunday, according to Accern. The research group ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Eagle Pharmaceuticals earned a news sentiment score of -0.08 on Accern's scale. They also assigned news coverage about the specialty pharmaceutical company an impact score of 44.43 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Who are Eagle Pharmaceuticals' major shareholders?

Eagle Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.42%), Park West Asset Management LLC (7.08%), Victory Capital Management Inc. (6.87%), Iridian Asset Management LLC CT (5.89%), LSV Asset Management (5.79%) and First Eagle Investment Management LLC (3.38%). Company insiders that own Eagle Pharmaceuticals stock include David Pernock, Douglas L Braunstein, Pete A Meyers, Proquest Investments Iv, LP, Richard A Edlin, Sander A Flaum, Sander A Flaum, Steven B Ratoff and Steven L Krill. View Institutional Ownership Trends for Eagle Pharmaceuticals.

Which institutional investors are selling Eagle Pharmaceuticals stock?

EGRX stock was sold by a variety of institutional investors in the last quarter, including Prudential Financial Inc., First Eagle Investment Management LLC, Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp, Old Mutual Global Investors UK Ltd., GSA Capital Partners LLP, Victory Capital Management Inc., Royal Bank of Canada and Iridian Asset Management LLC CT. View Insider Buying and Selling for Eagle Pharmaceuticals.

Which institutional investors are buying Eagle Pharmaceuticals stock?

EGRX stock was purchased by a variety of institutional investors in the last quarter, including LSV Asset Management, Guggenheim Capital LLC, UBS Group AG, Schwab Charles Investment Management Inc., BlackRock Inc., Park West Asset Management LLC, Virginia Retirement Systems ET AL and Federated Investors Inc. PA. Company insiders that have bought Eagle Pharmaceuticals stock in the last two years include David Pernock, Douglas L Braunstein, Pete A Meyers and Richard A Edlin. View Insider Buying and Selling for Eagle Pharmaceuticals.

How do I buy shares of Eagle Pharmaceuticals?

Shares of EGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eagle Pharmaceuticals' stock price today?

One share of EGRX stock can currently be purchased for approximately $65.36.

How big of a company is Eagle Pharmaceuticals?

Eagle Pharmaceuticals has a market capitalization of $969.62 million and generates $236.71 million in revenue each year. The specialty pharmaceutical company earns $51.94 million in net income (profit) each year or $3.37 on an earnings per share basis. Eagle Pharmaceuticals employs 108 workers across the globe.

How can I contact Eagle Pharmaceuticals?

Eagle Pharmaceuticals' mailing address is 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677. The specialty pharmaceutical company can be reached via phone at 201-326-5300 or via email at [email protected]


MarketBeat Community Rating for Eagle Pharmaceuticals (EGRX)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  295 (Vote Outperform)
Underperform Votes:  164 (Vote Underperform)
Total Votes:  459
MarketBeat's community ratings are surveys of what our community members think about Eagle Pharmaceuticals and other stocks. Vote "Outperform" if you believe EGRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EGRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Eagle Pharmaceuticals (NASDAQ:EGRX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Eagle Pharmaceuticals in the last 12 months. Their average twelve-month price target is $68.00, suggesting that the stock has a possible upside of 4.04%. The high price target for EGRX is $79.00 and the low price target for EGRX is $54.00. There are currently 1 sell rating and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.332.332.332.33
Ratings Breakdown: 1 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $68.00$63.3333$63.6667$62.3333
Price Target Upside: 4.04% upside20.91% upside7.87% upside12.68% upside

Eagle Pharmaceuticals (NASDAQ:EGRX) Consensus Price Target History

Price Target History for Eagle Pharmaceuticals (NASDAQ:EGRX)

Eagle Pharmaceuticals (NASDAQ:EGRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/17/2018MizuhoReiterated RatingUnderperform$54.00LowView Rating Details
2/26/2018Royal Bank of CanadaSet Price TargetBuy$71.00MediumView Rating Details
1/30/2018Piper Jaffray CompaniesReiterated RatingBuy$79.00MediumView Rating Details
11/2/2016William BlairBoost Price TargetOutperform$83.00 ➝ $97.00N/AView Rating Details
(Data available from 5/20/2016 forward)

Earnings

Eagle Pharmaceuticals (NASDAQ:EGRX) Earnings History and Estimates Chart

Earnings by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Eagle Pharmaceuticals (NASDAQ:EGRX) Earnings Estimates

2018 EPS Consensus Estimate: $2.45
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.33$0.33$0.33
Q2 20181$0.77$0.77$0.77
Q3 20181$0.59$0.59$0.59
Q4 20181$0.76$0.76$0.76

Eagle Pharmaceuticals (NASDAQ EGRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2018Q1 2018$0.68$0.53$48.88 million$46.60 millionViewN/AView Earnings Details
2/26/2018Q4 2017$1.00$0.84$53.65 million$46.80 millionViewListenView Earnings Details
11/8/2017Q3 2017$0.57$1.07$51.63 million$63.02 millionViewN/AView Earnings Details
8/9/2017Q2 2017$0.51$0.33$52.52 million$50.10 millionViewListenView Earnings Details
5/8/2017Q1 2017$1.44$1.42$70.10 million$76.80 millionViewListenView Earnings Details
3/1/2017Q416$2.24$3.52$86.13 million$81.10 millionViewListenView Earnings Details
11/9/2016Q316$0.71$0.73$41.04 million$37.80 millionViewListenView Earnings Details
8/9/2016Q216$0.71$0.80$43.55 million$40.90 millionViewN/AView Earnings Details
5/9/2016Q116$0.46($0.06)$29.07 million$29.60 millionViewN/AView Earnings Details
2/25/2016Q415$0.53$0.07$20.78 million$18.20 millionViewListenView Earnings Details
11/11/2015Q315($0.56)($0.65)$5.07 million$3.30 millionViewListenView Earnings Details
8/11/2015Q215($0.59)($0.53)$4.70 million$6.00 millionViewListenView Earnings Details
5/12/2015Q115$1.56$1.31$3.41 million$36.30 millionViewListenView Earnings Details
2/17/2015Q4 2014($0.39)$3.12 million$5.60 millionViewN/AView Earnings Details
12/17/2014Q314($0.49)($0.65)$2.90 million$2.81 millionViewN/AView Earnings Details
8/11/2014Q214($0.39)($0.21)$3.40 million$5.80 millionViewN/AView Earnings Details
5/14/2014Q114($0.26)($0.36)$3.20 million$5.00 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Eagle Pharmaceuticals (NASDAQ:EGRX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Eagle Pharmaceuticals (NASDAQ EGRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 19.50%
Insider Trading History for Eagle Pharmaceuticals (NASDAQ:EGRX)
Institutional Ownership by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Eagle Pharmaceuticals (NASDAQ EGRX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/6/2018Sander A FlaumDirectorSell2,340$53.94$126,219.60View SEC Filing  
8/16/2017Pete A MeyersCFOBuy350$55.45$19,407.50700View SEC Filing  
8/9/2017Douglas L BraunsteinDirectorBuy20,400$49.07$1,001,028.00View SEC Filing  
6/12/2017Pete A MeyersCFOBuy350$71.49$25,021.50350View SEC Filing  
5/19/2017David PernockInsiderBuy255$79.69$20,320.95966View SEC Filing  
5/16/2017David PernockInsiderBuy200$82.24$16,448.00711View SEC Filing  
4/25/2017Proquest Investments Iv, L.P.Major ShareholderSell54,180$88.38$4,788,428.40View SEC Filing  
4/3/2017Proquest Investments Iv, L.P.Major ShareholderSell91,332$83.09$7,588,775.88View SEC Filing  
3/29/2017Proquest Investments Iv, L.P.Major ShareholderSell106,468$83.01$8,837,908.68View SEC Filing  
3/28/2017Proquest Investments Iv, L.P.Major ShareholderSell6,182$83.02$513,229.64View SEC Filing  
3/27/2017Proquest Investments Iv, L.P.Major ShareholderSell39,431$83.00$3,272,773.00View SEC Filing  
3/23/2017Proquest Investments Iv, L.P.Major ShareholderSell1,200$83.05$99,660.00View SEC Filing  
3/23/2017Steven L KrillEVPSell14,125$81.07$1,145,113.755,023View SEC Filing  
3/22/2017Richard A EdlinDirectorBuy6,000$79.44$476,640.0029,400View SEC Filing  
3/21/2017David PernockInsiderBuy61$83.98$5,122.78511View SEC Filing  
3/20/2017Proquest Investments Iv, L.P.Major ShareholderSell100,000$82.06$8,206,000.00View SEC Filing  
3/9/2017David PernockInsiderBuy450$77.84$35,028.00450View SEC Filing  
1/4/2017Proquest Investments Iv, L.P.Major ShareholderSell65,114$85.16$5,545,108.24View SEC Filing  
12/13/2016Steven B RatoffDirectorSell10,000$75.01$750,100.0023,324View SEC Filing  
11/28/2016Sander A FlaumDirectorSell5,000$78.66$393,300.0011,374View SEC Filing  
11/11/2016Proquest Investments Iv, L.P.Major ShareholderSell34,486$85.15$2,936,482.90View SEC Filing  
11/9/2016Proquest Investments Iv, L.P.Major ShareholderSell153,830$79.29$12,197,180.70View SEC Filing  
11/7/2016Proquest Investments Iv, L.P.Major ShareholderSell5,030$75.39$379,211.70View SEC Filing  
11/4/2016Proquest Investments Iv, L.P.Major ShareholderSell245,770$71.02$17,454,585.40View SEC Filing  
9/30/2016Proquest Investments Iv, L.P.Major ShareholderSell22,100$70.06$1,548,326.00View SEC Filing  
9/29/2016Proquest Investments Iv, L.P.Major ShareholderSell77,900$70.04$5,456,116.00View SEC Filing  
9/21/2016Proquest Investments Iv, L.P.Major ShareholderSell99,795$66.17$6,603,435.15View SEC Filing  
9/8/2016Proquest Investments Iv, L.P.Major ShareholderSell70,925$62.50$4,432,812.50View SEC Filing  
8/24/2016Proquest Investments Iv, L.P.Major ShareholderSell28,870$63.00$1,818,810.00View SEC Filing  
8/17/2016Proquest Investments Iv, L.P.Major ShareholderSell99,795$61.36$6,123,421.20View SEC Filing  
8/16/2016Proquest Investments Iv, L.P.Major ShareholderSell60,150$61.67$3,709,450.50View SEC Filing  
8/15/2016Proquest Investments Iv, L.P.Major ShareholderSell24,949$60.77$1,516,150.73View SEC Filing  
5/13/2016Proquest Management LlcMajor ShareholderSell17,980$40.72$732,145.60View SEC Filing  
4/1/2016Scott TarriffCEOSell30,765$40.63$1,249,981.951,369,946View SEC Filing  
3/15/2016Michael GravesDirectorBuy1,000$56.73$56,730.001,000View SEC Filing  
2/1/2016Scott TarriffCEOSell18,360$68.08$1,249,948.801,420,491View SEC Filing  
12/22/2015Sander A. FlaumDirectorSell13,025$54.81$713,900.2516,374View SEC Filing  
12/1/2015Scott TarriffCEOSell14,050$88.93$1,249,466.501,453,400View SEC Filing  
11/2/2015Scott TarriffCEOSell19,339$64.63$1,249,879.571,467,450View SEC Filing  
10/1/2015Scott TarriffCEOSell17,878$69.92$1,250,029.761,486,789View SEC Filing  
9/1/2015Scott TarriffCEOSell16,245$76.95$1,250,052.751,504,667View SEC Filing  
7/1/2015Scott TarriffCEOSell135,710$46.34$6,288,801.40View SEC Filing  
6/16/2015Steven L KrillInsiderSell9,980$81.60$814,368.00View SEC Filing  
2/18/2014Jay MoorinDirectorBuy333,333$15.00$4,999,995.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Eagle Pharmaceuticals (NASDAQ EGRX) News Headlines

Source:
DateHeadline
Eagle Pharmaceuticals (EGRX) Rating Increased to Strong-Buy at BidaskClubEagle Pharmaceuticals (EGRX) Rating Increased to Strong-Buy at BidaskClub
www.americanbankingnews.com - May 19 at 1:01 PM
Form 8-K EAGLE PHARMACEUTICALS, For: May 16Form 8-K EAGLE PHARMACEUTICALS, For: May 16
www.streetinsider.com - May 18 at 9:38 AM
Eagle Pharmaceuticals, Inc. Granted Final FDA Approval for Bendamustine Hydrochloride Ready-to-Dilute Solution in ...Eagle Pharmaceuticals, Inc. Granted Final FDA Approval for Bendamustine Hydrochloride Ready-to-Dilute Solution in ...
www.businesswire.com - May 18 at 9:38 AM
BRIEF-Eagle Pharmaceuticals Gets Final FDA Approval For Bendamustine Hydrochloride Ready-To-Dilute Solution In ...BRIEF-Eagle Pharmaceuticals Gets Final FDA Approval For Bendamustine Hydrochloride Ready-To-Dilute Solution In ...
www.reuters.com - May 18 at 9:38 AM
$51.50 Million in Sales Expected for Eagle Pharmaceuticals (EGRX) This Quarter$51.50 Million in Sales Expected for Eagle Pharmaceuticals (EGRX) This Quarter
www.americanbankingnews.com - May 18 at 1:42 AM
Eagle Pharmaceuticals (EGRX) Underperform Rating Reaffirmed at MizuhoEagle Pharmaceuticals' (EGRX) Underperform Rating Reaffirmed at Mizuho
www.americanbankingnews.com - May 17 at 3:27 PM
Market Trends Toward New Normal in Agios Pharmaceuticals, Corcept Therapeutics ...Market Trends Toward New Normal in Agios Pharmaceuticals, Corcept Therapeutics ...
globenewswire.com - May 17 at 9:13 AM
Eagle Pharmaceuticals (EGRX) Expected to Announce Earnings of $0.96 Per ShareEagle Pharmaceuticals (EGRX) Expected to Announce Earnings of $0.96 Per Share
www.americanbankingnews.com - May 16 at 11:12 PM
Eagle Pharmaceuticals (EGRX) Says it was Granted Final FDA Approval for Bendamustine Hydrochloride Ready-to-Dilute Solution in 500ml AdmixtureEagle Pharmaceuticals (EGRX) Says it was Granted Final FDA Approval for Bendamustine Hydrochloride Ready-to-Dilute Solution in 500ml Admixture
www.streetinsider.com - May 16 at 4:54 PM
Eagle Pharmaceuticals, Inc. Granted Final FDA Approval for Bendamustine Hydrochloride Ready-to-Dilute Solution in a 500ml AdmixtureEagle Pharmaceuticals, Inc. Granted Final FDA Approval for Bendamustine Hydrochloride Ready-to-Dilute Solution in a 500ml Admixture
finance.yahoo.com - May 16 at 9:14 AM
FDA approves Eagle Pharmaceuticals RTD HCI solution in a 500ml admixtureFDA approves Eagle Pharmaceuticals' RTD HCI solution in a 500ml admixture
seekingalpha.com - May 16 at 7:52 AM
Eagle Pharmaceuticals (EGRX) Upgraded to Hold at ValuEngineEagle Pharmaceuticals (EGRX) Upgraded to Hold at ValuEngine
www.americanbankingnews.com - May 11 at 11:13 AM
Edited Transcript of EGRX earnings conference call or presentation 10-May-18 12:30pm GMTEdited Transcript of EGRX earnings conference call or presentation 10-May-18 12:30pm GMT
finance.yahoo.com - May 11 at 9:42 AM
Eagle Pharmaceuticals (EGRX) Releases  Earnings Results, Misses Estimates By $0.16 EPSEagle Pharmaceuticals (EGRX) Releases Earnings Results, Misses Estimates By $0.16 EPS
www.americanbankingnews.com - May 10 at 5:47 PM
Eagle Pharmaceuticals (EGRX) CEO Scott Tarriff on Q1 2018 Results - Earnings Call TranscriptEagle Pharmaceuticals' (EGRX) CEO Scott Tarriff on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 5:05 PM
Eagle Pharmaceuticals (EGRX) Sell Rating Reaffirmed at MizuhoEagle Pharmaceuticals' (EGRX) Sell Rating Reaffirmed at Mizuho
www.americanbankingnews.com - May 10 at 3:07 PM
Eagle Pharmaceuticals misses by $0.14, misses on revenueEagle Pharmaceuticals misses by $0.14, misses on revenue
seekingalpha.com - May 10 at 9:10 AM
Eagle Pharmaceuticals: 1Q Earnings SnapshotEagle Pharmaceuticals: 1Q Earnings Snapshot
finance.yahoo.com - May 10 at 9:10 AM
Eagle Pharmaceuticals (EGRX) Upgraded to "Buy" by BidaskClubEagle Pharmaceuticals (EGRX) Upgraded to "Buy" by BidaskClub
www.americanbankingnews.com - May 9 at 6:39 PM
Eagle (EGRX) Denied Unique Ryanodex J-Code - MizuhoEagle (EGRX) Denied Unique Ryanodex J-Code - Mizuho
www.streetinsider.com - May 7 at 4:59 PM
Eagle Pharmaceuticals (EGRX) Downgraded by ValuEngine to "Sell"Eagle Pharmaceuticals (EGRX) Downgraded by ValuEngine to "Sell"
www.americanbankingnews.com - May 3 at 11:33 PM
Eagle Pharmaceuticals, Inc. to Discuss First Quarter 2018 Financial Results on May 10, 2018Eagle Pharmaceuticals, Inc. to Discuss First Quarter 2018 Financial Results on May 10, 2018
finance.yahoo.com - May 1 at 4:43 PM
$46.35 Million in Sales Expected for Eagle Pharmaceuticals (EGRX) This Quarter$46.35 Million in Sales Expected for Eagle Pharmaceuticals (EGRX) This Quarter
www.americanbankingnews.com - May 1 at 3:35 AM
Eagle Pharmaceuticals, Inc. to Present at 43rd Annual Deutsche Bank Health Care ConferenceEagle Pharmaceuticals, Inc. to Present at 43rd Annual Deutsche Bank Health Care Conference
finance.yahoo.com - April 30 at 4:44 PM
$0.60 Earnings Per Share Expected for Eagle Pharmaceuticals (EGRX) This Quarter$0.60 Earnings Per Share Expected for Eagle Pharmaceuticals (EGRX) This Quarter
www.americanbankingnews.com - April 29 at 11:12 AM
Eagle Pharmaceuticals (EGRX) Given Average Recommendation of "Hold" by BrokeragesEagle Pharmaceuticals (EGRX) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - April 26 at 9:38 AM
BidaskClub Downgrades Eagle Pharmaceuticals (EGRX) to SellBidaskClub Downgrades Eagle Pharmaceuticals (EGRX) to Sell
www.americanbankingnews.com - April 18 at 12:16 PM
William Blair Analysts Reduce Earnings Estimates for Eagle Pharmaceuticals (EGRX)William Blair Analysts Reduce Earnings Estimates for Eagle Pharmaceuticals (EGRX)
www.americanbankingnews.com - April 18 at 7:58 AM
Eagle Pharmaceuticals (EGRX) to Post Q2 2018 Earnings of $0.77 Per Share, William Blair ForecastsEagle Pharmaceuticals (EGRX) to Post Q2 2018 Earnings of $0.77 Per Share, William Blair Forecasts
www.americanbankingnews.com - April 17 at 6:45 AM
Eagle Pharmaceuticals’ Vasopressin ANDA Accepted for Filing by the FDAEagle Pharmaceuticals’ Vasopressin ANDA Accepted for Filing by the FDA
finance.yahoo.com - April 16 at 8:56 AM
Mizuho Trims Eagle Pharmaceuticals (EGRX) Target Price to $40.00Mizuho Trims Eagle Pharmaceuticals (EGRX) Target Price to $40.00
www.americanbankingnews.com - April 15 at 5:39 PM
Eagle Pharmaceuticals (EGRX) Price Target Cut to $81.00Eagle Pharmaceuticals (EGRX) Price Target Cut to $81.00
www.americanbankingnews.com - April 15 at 5:06 PM
Eagle Pharmaceuticals (EGRX) Cut to Strong Sell at BidaskClubEagle Pharmaceuticals (EGRX) Cut to Strong Sell at BidaskClub
www.americanbankingnews.com - April 14 at 11:26 PM
 Brokerages Expect Eagle Pharmaceuticals (EGRX) Will Post Quarterly Sales of $49.18 Million Brokerages Expect Eagle Pharmaceuticals (EGRX) Will Post Quarterly Sales of $49.18 Million
www.americanbankingnews.com - April 14 at 3:51 AM
Eagle Pharmaceuticals (EGRX) Downgraded by ValuEngine to "Buy"Eagle Pharmaceuticals (EGRX) Downgraded by ValuEngine to "Buy"
www.americanbankingnews.com - April 13 at 1:35 PM
 Brokerages Expect Eagle Pharmaceuticals (EGRX) to Announce $0.84 Earnings Per Share Brokerages Expect Eagle Pharmaceuticals (EGRX) to Announce $0.84 Earnings Per Share
www.americanbankingnews.com - April 12 at 11:19 AM
Eagle Pharmaceuticals (EGRX) Upgraded at ValuEngineEagle Pharmaceuticals (EGRX) Upgraded at ValuEngine
www.americanbankingnews.com - April 8 at 12:54 PM
Head to Head Survey: Mersana Therapeutics (MRSN) versus Eagle Pharmaceuticals (EGRX)Head to Head Survey: Mersana Therapeutics (MRSN) versus Eagle Pharmaceuticals (EGRX)
www.americanbankingnews.com - April 4 at 5:22 PM
Eagle Pharmaceuticals Inc (EGRX) Receives Average Rating of "Hold" from AnalystsEagle Pharmaceuticals Inc (EGRX) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - April 1 at 11:38 AM
Eagle Pharmaceuticals (EGRX) Given "Outperform" Rating at Royal Bank of CanadaEagle Pharmaceuticals (EGRX) Given "Outperform" Rating at Royal Bank of Canada
www.americanbankingnews.com - March 31 at 6:34 PM
Eagle Pharmaceuticals (EGRX) Lowered to Hold at ValuEngineEagle Pharmaceuticals (EGRX) Lowered to Hold at ValuEngine
www.americanbankingnews.com - March 31 at 2:40 PM
Eagle Pharmaceuticals (EGRX) Secures New Patent for Eagle BiologicsEagle Pharmaceuticals (EGRX) Secures New Patent for Eagle Biologics
www.streetinsider.com - March 28 at 4:46 PM
Eagle Pharmaceuticals (EGRX) Lowered to "Hold" at BidaskClubEagle Pharmaceuticals (EGRX) Lowered to "Hold" at BidaskClub
www.americanbankingnews.com - March 27 at 3:28 PM
Eagle Pharmaceuticals Announces New Patent for Eagle BiologicsEagle Pharmaceuticals Announces New Patent for Eagle Biologics
finance.yahoo.com - March 27 at 9:23 AM
Eagle Pharmaceuticals (EGRX) Given Buy Rating at Piper JaffrayEagle Pharmaceuticals (EGRX) Given Buy Rating at Piper Jaffray
www.americanbankingnews.com - March 26 at 1:26 PM
ValuEngine Lowers Eagle Pharmaceuticals (EGRX) to HoldValuEngine Lowers Eagle Pharmaceuticals (EGRX) to Hold
www.americanbankingnews.com - March 25 at 6:26 PM
BidaskClub Downgrades Eagle Pharmaceuticals (EGRX) to HoldBidaskClub Downgrades Eagle Pharmaceuticals (EGRX) to Hold
www.americanbankingnews.com - March 24 at 4:30 PM
Head to Head Survey: Eagle Pharmaceuticals (EGRX) vs. Tactile Systems Technology (TCMD)Head to Head Survey: Eagle Pharmaceuticals (EGRX) vs. Tactile Systems Technology (TCMD)
www.americanbankingnews.com - March 21 at 11:10 PM
Eagle Pharmaceuticals (EGRX) Rating Reiterated by MizuhoEagle Pharmaceuticals (EGRX) Rating Reiterated by Mizuho
www.americanbankingnews.com - March 21 at 7:48 PM
Eagle Pharmaceuticals: New Clarity On Past Overhangs Reveals Solid Value Opportunity - Seeking AlphaEagle Pharmaceuticals: New Clarity On Past Overhangs Reveals Solid Value Opportunity - Seeking Alpha
seekingalpha.com - March 9 at 5:57 PM

SEC Filings

Eagle Pharmaceuticals (NASDAQ:EGRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Eagle Pharmaceuticals (NASDAQ:EGRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Eagle Pharmaceuticals (NASDAQ EGRX) Stock Chart for Sunday, May, 20, 2018

Loading chart…

This page was last updated on 5/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.